Conditions: Exercise-induced Pulmonary Arterial Hypertension
Keywords: Exercise-induced pulmonary arterial hypertension (EIPAH) Pulmonary arterial hypertension (PAH) ambrisentan Advanced cardiopulmonary exercise test (CPET)
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 30
Healthy volunteers: no

Brief summary:
The purpose of this study is assess whether ambrisentan can help people with exercise- induced pulmonary arterial hypertension (EIPAH). The investigators also want to find out if ambrisentan is safe to take without causing excessive side effects.

Detailed description:
EIPAH population: These participants may provide a unique window into the pathogenesis of PAH. Our data suggest that these participants may represent an early phase of PAH with an abnormal vascular response.

The study includes an assessment of the potential impact of ambrisentan on the exercise capacity Advanced Level-3 cardiopulmonary exercise test (CPET) and the World Health Organization functional class (WHO FC).

Arms:
arm 1: Open-label ambrisentan

Interventions: intervention 1: Ambrisentan
Intervention descriptions: intervention 1: 5 mg orally every day for 4 weeks. At Week 4, if ambrisentan 5 mg was tolerated, the dose was increased to 10 mg every day for the remainder of the 24-week period.

Protocol document: